Predictors of negotiated prices for new drugs in Germany.

ABSTRACT:

Introduction

In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal Joint Committee with subsequent price negotiation and optional arbitration. The purpose of this study was to identify drivers of negotiated (including arbitrated) prices of new, non-orphan innovative medicines in Germany.

Methods

The analysis considered all non-orphan drugs that underwent a benefit appraisal between January 2011 and June 2016, and displayed a reimbursement price in the German Drug Directory (Lauer-Taxe^®) in November 2017. Negotiated annual treatment costs were analyzed with respect to 11 explanatory variables in regression models.

Results

The total sample included 106 non-orphan drugs. The analysis showed a significant and

SUBMITTER: Gandjour A 

PROVIDER: S-EPMC7423852 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature